Genetron Holdings, which provides DNA sequencing-based diagnostic services for cancer patients in China, raised $256 million by offering 16 million ADSs at $16, well above the range of $11.50 to $13.50. The company upsized its offering on Thursday from 13 million ADSs. At pricing, the company commands a fully diluted market value of $1.5 billion (+34% vs. midpoint).
Genetron Holdings plans to list on the Nasdaq under the symbol GTH. Credit Suisse, CICC, BTIG and Canaccord Genuity acted as lead managers on the deal.
